Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 911 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Peritoneum Cancer Clear all
Completed Phase 1 Interventional

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

NCT00183859
View directory record Official record
Conditions
Adenocarcinoma, Gastric Cancer
Interventions
irinotecan
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00459290
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
mifepristone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 30, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374
View directory record Official record
Conditions
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions
Tremelimumab, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated Not applicable Interventional

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

NCT00028782
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Malignant Ascites, Primary Peritoneal Cavity Cancer, Recurrent Malignant Mesothelioma
Interventions
etanidazole, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 30, 2026, 1:46 PM EDT
Withdrawn Phase 1Phase 2 Interventional

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

NCT00603460
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
DCVax-L and T Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

NCT00501644
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Carboplatin, GM-CSF (Sargramostim), Interferon Gamma
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 30, 2026, 1:46 PM EDT
Active, not recruiting Early Phase 1 Interventional

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

NCT05415709
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Biospecimen Collection, Diagnostic Imaging
Drug · Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

NCT03054909
View directory record Official record
Conditions
FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer, FIGO Stage III Primary Peritoneal Cancer
Interventions
ALT-803 Subcutaneous, ALT-803 Intraperitoneal
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02470585
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasm
Interventions
Veliparib, Paclitaxel, Carboplatin, Placebo to Veliparib
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
135
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Results available

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

NCT00702299
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel, pemetrexed disodium, biologic sample preservation procedure
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Early Phase 1 Interventional

Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01670799
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Ketorolac
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 30, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

NCT05114421
View directory record Official record
Conditions
High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Lenvatinib, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery

NCT02356471
View directory record Official record
Conditions
Malignant Gastrointestinal Neoplasm, Malignant Peritoneal Neoplasm
Interventions
Management of Therapy Complications Fitbit Zip (portable pedometer device), Questionnaire Administration, Quality-of-Life Assessment
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 30, 2026, 1:46 PM EDT
Recruiting Phase 1 Interventional

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

NCT06856499
View directory record Official record
Conditions
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Cirtuvivint, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

NCT01447706
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
MM-121, Paclitaxel
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Glendale, Arizona • Scottsdale, Arizona • Bakersfield, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 30, 2026, 1:46 PM EDT
Recruiting Phase 1 Interventional

A Study of Sovilnesib in Subjects With Ovarian Cancer

NCT06084416
View directory record Official record
Conditions
High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Interventions
Sovilnesib
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Newport Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

NCT05691504
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cobimetinib, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pelcitoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

NCT00055432
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer
Interventions
Gemzar and Alimta
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2006 · Synced Oct 30, 2026, 1:46 PM EDT
Terminated No phase listed Observational

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00897806
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Microarray analysis, Laboratory biomarker analysis
Genetic · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 30, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine

NCT00293293
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Primary Cancer, Fallopian Tube Cancer
Interventions
healing touch, massage therapy, hypnosis, Standard chemotherapy
Other · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03579316
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Adavosertib, Olaparib, Ceralasertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 1:46 PM EDT
Not yet recruiting Phase 2 Interventional

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

NCT06295094
View directory record Official record
Conditions
Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases, Minimally Invasive Surgical Procedures
Interventions
Cisplatin, Doxorubicin
Drug
Lead sponsor
Odense University Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 30, 2026, 1:46 PM EDT